The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.

ABSTRACT:

SUBMITTER: Cretella D 

PROVIDER: S-EPMC5872523 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature